Related Articles
Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival
Expression of E-cadherin and KRAS mutation may serve as biomarkers of cetuximab-based therapy in metastatic colorectal cancer
Association between specific KRAS mutations and the clinicopathological characteristics of colorectal tumors
A novel approach to detect KRAS/BRAF mutation for colon cancer: Highly sensitive simultaneous detection of mutations and simple pre-treatment without DNA extraction
Safety and efficacy of panitumumab therapy after metastatic colorectal cancer progression with cetuximab: Experience at a single Japanese institution